annb0t
Top 20
Mesoblast Limited
Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended March 31, 2022.
Financial Highlights
Net cash usage reported for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 ...
>>> Read more: Operational Highlights and Financial Results for the Period Ended March 31, 2022
Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended March 31, 2022.
Financial Highlights
Net cash usage reported for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 ...
>>> Read more: Operational Highlights and Financial Results for the Period Ended March 31, 2022
